A Phase 1/2, Multicenter, Open-label Trial of Oncolytic MG1 Expressing Mutant Human Papilloma Virus (HPV) E6 and E7 (MG1-E6E7), with Adenovirus Vaccine Expressing Mutant HPV E6 and E7 (Ad-E6E7) in Patients with HPV Positive Solid Tumours

July 1, 2017 to March 31, 2020

Highlights

• Evaluate the safety and anti-tumour activity of Ad/MG1-E6E7 in patients with HPV-associated tumours.
• Based upon oncolytic vaccine technology with a proven safety profile and unprecedented immune boosting activity.
• Open the trial at minimum of five Canadian sites.

About the project

Novel immunotherapy agents that target the immune system in order to treat tumours are revolutionizing cancer care. However, only 10-40% of patients respond to treatment, depending on the therapeutic agent and the indication. Therefore, novel agents with unique mechanisms-of-action are needed. Oncolytic virus vaccines infect and lyse tumour cells while inducing durable anti-tumour immunity by expression of tumour-associated antigens. This team of researchers has made a next-generation oncolytic virus vaccine that is designed to address a major unmet medical need: cancers associated with the human papilloma virus (HPV). HPV causes virtually all cervical cancers in the world, the majority of head and neck cancers in industrialized countries and a variety of other tumours (e.g. oesophageal and anal). Approximately 5% of the world’s cancer burden is caused by HPV.

HPV-associated tumours are an ideal indication for oncolytic vaccine technology as the HPV antigens are foreign (therefore highly immunogenic) and also drivers of tumourigenicity (therefore the tumour is not likely to lose expression of the antigen). This project aims to test in a clinical trial a new immune therapeutic strategy for patients with advanced cancers having failed conventional therapies. Specifically, the team have developed an oncolytic virus vaccine technology that takes advantage of the unique biology of a certain virus discovered by members of their team.

This project will evaluate the safety and anti-tumour activity of Ad/MG1-E6E7 in patients with HPV-associated tumours. In addition, anti-E6 and E7 immune responses will be monitored on the study, potentially providing a basis for the evaluation of the oncolytic virus vaccine technology in combination with other cancer immunotherapies in the future.

If clinical responses are observed on the proposed study, a pivotal study of Ad/MG1-E6E7 in an HPV-associated tumour indication is planned.
Clinical trial sites and investigators

Clinical Trial Sites:
Phase I:
- Princess Margaret Cancer Centre
- The Ottawa Hospital
- Juravinski Cancer Centre

Potential Phase II sites:
- Jewish General Hospital
- British Columbia Cancer Agency
- University of Calgary

Ottawa
- The Ottawa Hospital
- Ottawa Hospital Research Institute
- Turnstone Biologics
- University of Ottawa
- Dr. Guy Ungerechts
- Dr. John Bell
- Dr. Caroline Breitbach
- Dr. Chantal Lemay

Toronto
- Princess Margaret Cancer Centre
- Dr. Amit Oza

Hamilton
- Juravinski Cancer Centre
- McMaster University
- McMaster Immunology Research Centre
- Turnstone Biologics
- Dr. Brian Lichty
- Dr. Jonathan Bramson
- Dr. Hal Hirte
- Dr. Sebastien Hotte
- Dr. Gregory Pond

Partner contributions
Turnstone Biologics
$5,221,400 will be the study sponsor, handle all regulatory interactions, and provide the bulk of the funding to complete the proposed study.

BioCanRx
$780,665 approved on April 28, 2017

2017
- Obtain Health Canada No Objection Letter (NOL)
- 1st site activated (Q4)

2018
- First patient enrolled (Q1)
- Start Phase 2 (known dose, Q3)

2019
- Last patient in (Q3)

2020
- Database lock (Q1)
- Complete correlate testing (Q1)

The power to kill cancer lies within us. Let’s tell our bodies how.

BioCanRx
Biotherapeutics for Cancer Treatment
Biothérapies pour le traitement du cancer